{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 53,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "before_after",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Uses a before-after visual comparison to explain the mechanism of action.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/14",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.275,
        "x": 0.708,
        "y": 0.185
      },
      "kind": "callout",
      "text": "ANEB-001 is a competitive antagonist at the human CB1 receptor with an affinity of 0.6nM. Good bioavailability and brain penetration (brain:plasma ratio = 1.5). Antagonizes THC-induced hypolocomotion in mice.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ea35f17-3cba-4db4-9658-32071e2401ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": "Diagram showing THC binding to CB1 receptor and ANEB-001 displacing THC",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "832bfdfc-5978-4888-b87e-f8e6f132582f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "Comparison of potential effects with and without ANEB-001",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dc7f987-5536-4778-bfd2-bb54d18863ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Well-understood pharmacology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f65a1172-8048-4f5e-9f60-09a13ef52401",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "07e20a91-a5ff-45ac-9409-7940a1d458bb",
      "evidence": "callout/primary: ANEB-001 is a competitive antagonist at the human CB1 receptor with an affinity of 0.6nM.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "546cfd2c-aa69-4531-b7e6-d545d06ee246",
      "evidence": "Visual comparison of state without drug vs state with drug",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}